EXCLUSIVE: Context Therapeutics Co-Founder & CEO, Martin Lehr Now Interviewing On Benzinga’s ‘All-Access’ Show
Click To Tune In Here... https://www.youtube.com/watch?v=vLBRC8C_X3o
Context Therapeutics Q2 EPS $(0.25)
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.25) per share.
69 Biggest Movers From Friday
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
40 Stocks Moving In Friday’s Mid-Day Session
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
66 Biggest Movers From Friday
Gainers
GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
35 Stocks Moving In Monday’s Mid-Day Session
Gainers
Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors.
ThinkEquity Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $10
ThinkEquity initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $10.